Evidence

13 articles available

Permanent injunctions granted in 94 per cent of the patent decisions examined. Proportionality expressly assessed in 0.6 per cent. Since January these two figures, taken from the executive summary of…

In Sanofi and Regeneron v. Amgen, the Düsseldorf Local Division upheld a second medical use patent but dismissed the infringement action. The difficulty was proving that the medicine would be…

The disclosure decision comes firstA comparable licence is never only evidence of a rate. Before the Unified Patent Court, pleading one may open it to an employee of the opponent, keep that employee…

A compass worth havingThe 7th Civil Chamber of the Landgericht München I has done something no European court had done before. On 13 August 2026 it published guidelines, sixty-seven pages long,…

The first question before a European launch is not whether the product infringes. It is where, against whom, on what record and on what timetable that question will be tested. Market-entry opinions…

The first strategic choice in a patent dispute is not where to sue. It is where to secure the evidence that will make the claim pleadable, quantifiable and commercially credible. A case may…

This week, I have the pleasure of speaking in Amsterdam at C5’s 19th Annual Forum on Pharma & Biotech Patent Litigation in Europe, in a panel devoted to running and defending preliminary injunctions…

Forget about Gangnam Style, it is overrated. Aya Nakamura Djadja is more than ever the dance-floor song of the moment (especially since her performance at the 2024 Olympics Game opening ceremony). Is…

Regular readers of this blog will be aware of my interest, or rather my passion, for several Patent Law topics, including notably SEPs (see notably here, here and here), proof of infringement (see…